PharmiWeb Recruiter Blog

• Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia
• Collaboration with Syneos Health to effectively reach the primary care market in Europe and Canada

Allschwil, Switzerland & Morrisville, N.C. – January 26, 2022
Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health^® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada.

• PARTNERSHIP LEVERAGES EVOTEC’S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS 
• AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS

Hamburg 25 January 2022:
Evotec announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (“iPSC”)-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. 

Through phenotypic screening of human iPSC-derived cells, supported by Evotec’s PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic interventions. Boehringer Ingelheim will then continue with the discovery and development of potential therapeutic candidates. Besides an undisclosed upfront and FTE-based research payment, Evotec will continue to benefit from the successful further development of the candidates in the form of milestones and layered royalties.

Vetter Development Service Rankweil receives manufacturing authorization

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2022 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s sixth inclusion on the list. Ranked 32nd, Eisai was the highest ranking company among global pharmaceutical companies (please visit here for the Global 100 ranking).

• COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT...

• Enables sharing of, and access to, novel datasets and tools through Eagle Genomics’ e[datascientist]™ platform
• Agreement will facilitate understanding of complex relationships between microbiome, food and other factors, including potential causes of health and disease

Cambridge and Norwich, UK – 13 January 2022 - Today, Eagle Genomics, the Deep Tech software business pioneering the application of network science to biology, and the Quadram Institute, a world-leading institute creating new interfaces between food science, gut biology, and human health, are pleased to announce a new partnership committed to promoting the understanding of microbiome science. Building on the agreement announced in September 2021 with the Earlham Institute, a Norwich-based leader in data-intensive bioscience research, the partnership with the Quadram Institute will involve the sharing of datasets, innovation pipelines and tools to facilitate the understanding of complex microbiome data through Eagle Genomics’ e[datascientist]™ platform.

The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action